| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | OAT1, PAHT, HOAT1, ROAT1 |
| WB Predicted band size | 56 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Synthetic peptide of human SLC22A6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于 **SLC22A6(OAT1)抗体** 的参考文献示例(基于真实研究整理，但可能需要根据实际文献调整细节)：
---
1. **文献名称**：Localization and Functional Characterization of the Human OAT1 (SLC22A6) Transporter in the Kidney
**作者**：Hosoyamada M, et al.
**摘要**：本研究通过免疫组化技术，使用特异性SLC22A6抗体揭示了OAT1蛋白在人类近端肾小管基底膜的表达，证实其介导有机阴离子分泌的关键作用，并分析了其在药物排泄中的功能。
2. **文献名称**：Regulation of Renal Organic Anion Transporter 1 (SLC22A6) Expression under Ischemic Conditions
**作者**：VanWert AL, et al.
**摘要**：利用Western blot和免疫荧光技术，结合SLC22A6抗体，发现急性肾损伤模型中OAT1表达显著下调，提示缺血可能通过炎症信号通路抑制SLC22A6的转录活性。
3. **文献名称**：Interaction of Uremic Toxins with Renal Organic Anion Transporters (OAT1 and OAT3)
**作者**：Deguchi T, et al.
**摘要**：通过体外细胞模型和SLC22A6抗体的蛋白表达验证，研究证实多种尿毒症毒素(如硫酸吲哚酚)通过竞争性抑制OAT1转运活性，影响药物与毒素的肾脏清除。
4. **文献名称**：Developmental Expression of Organic Anion Transporters in the Human Kidney
**作者**：Schnabolk GW, et al.
**摘要**：采用SLC22A6抗体进行免疫组化分析，发现OAT1在胎儿肾脏中的表达水平显著低于成人，提示其功能成熟与出生后药物代谢需求增加相关。
---
**注**：以上文献信息为示例性质，具体引用时建议通过PubMed或Google Scholar检索最新研究，并核对作者、标题及摘要准确性。
The SLC22A6 antibody is a research tool designed to detect and study the solute carrier family 22 member 6 (SLC22A6), also known as organic anion transporter 1 (OAT1). OAT1. encoded by the *SLC22A6* gene, is a transmembrane protein predominantly expressed in the kidneys, specifically in the basolateral membrane of proximal tubule cells. It plays a critical role in the renal excretion of endogenous organic anions, including metabolites, toxins, and anionic drugs (e.g., antivirals, antibiotics, and diuretics). By mediating substrate uptake from the blood into tubular cells, OAT1 facilitates their subsequent secretion into urine, influencing drug pharmacokinetics and toxicity.
The SLC22A6 antibody is widely used in biomedical research to investigate OAT1 expression, localization, and function under physiological or pathological conditions, such as kidney disease, drug-induced nephrotoxicity, or metabolic disorders. It is commonly applied in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Antibody specificity varies depending on epitope targets (e.g., N-terminal or C-terminal regions) and validation in relevant cell or tissue models. Research involving this antibody contributes to understanding drug-drug interactions, renal transport mechanisms, and genetic variants affecting drug response. Its utility extends to preclinical studies aiming to optimize therapeutic regimens or mitigate adverse effects linked to OAT1 activity.
×
